UNCLASSIFIED

AD NUMBER

ADB232218

NEW LIMITATION CHANGE

TO

Approved for public release, distribution unlimited

FROM

Distribution authorized to U.S. Gov't. agencies only; Proprietary Information; Jul 96. Other requests shall be referred to US Army Medical Research and Materiel Command, Attn: MCMR-RMI-S, Fort Detrick, Frederick, MD 21702-5012.

AUTHORITY

USAMRMC Ltr., 10 Aug 98

ΑD			

MILITARY INTERDEPARTMENTAL PURCHASE REQUEST NUMBER 95MM5535

TITLE: Clinical Impact of Hepatitis C Infection in Military Active Duty Women

PRINCIPAL INVESTIGATOR: COL Maria H. Sjogren

CONTRACTING ORGANIZATION: Walter Reed Army Medical Center Washington, DC 20307-5001

REPORT DATE: July 1996

TYPE OF REPORT: Final

PREPARED FOR: Commander

U.S. Army Medical Research and Materiel Command Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, July 1996). Other requests for this document shall be referred to Commander, U.S. Army Medical Research and Materiel Command, ATTN: MCMR-RMI-S, Fort Detrick, Frederick, MD 21702-5012.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Lefterson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE July 1996	3. REPORT TYPE AND	D DATES COVERED 94 - 31 Dec 95)		
4. TITLE AND SUBTITLE Clinica			5. FUNDING NUMBERS		
Infection in Military Act	tive Duty Women		95MM5535		
6. AUTHOR(S)					
COL Maria H. Sjogren					
oon marra m. bjogrem					
7. PERFORMING ORGANIZATION NAMI Walter Reed Army Medical			8. PERFORMING ORGANIZATION REPORT NUMBER		
Washington, DC 20307-500			TIET ON NOWDEN		
,					
9. SPONSORING/MONITORING AGENC	Y NAME(S) AND ADDRESS(ES)		10. SPONSORING/MONITORING		
U.S. Army Medical Research		and	AGENCY REPORT NUMBER		
Fort Detrick					
Frederick, Maryland 2170	02-5012				
		·			
11. SUPPLEMENTARY NOTES					
12a. DISTRIBUTION / AVAILABILITY ST	ATEMENT		12b. DISTRIBUTION CODE		
Distribution authorized t					
(proprietary information, this document can be made	_	_			
Research and Materiel Com	mmand, ATTN: MCMR-RN	MI-S. Fort DTM	QUALITY INSPECTED &		
Research and Materiel Command, ATTN: MCMR-RMI-S, Fort DTM QUALITY INSPECTED & Detrick, Frederick, MD 21702-5012					
13. ABSTRACT (Maximum 200					
To determine the prevalence of					
studied: 464 healthy women, 3					
of diagnosis (not liver disease). HCV epidemiological risks were sought. Sera were tested for ALT and					
anti-HCV (ELISA, RIBA, Ortho Lab). HCV RNA and HCV genotype were determined (Inno-LIPA,					
Belgium). Data analysis showed a mean age of 31.5 yrs (18-55). Racial distribution was 59% White,					
29% Black, 7% Hispanic, 2% Asian. Overall 2.7% had abnormal ALT, eight (1.7%) healthy and 18					
(3.7%) ill women. Mean abnormal ALT: 90, range: 53-260. Eleven women (1.16%) had anti-HCV.					
HCV infection was 1.7% (8) for healthy women and 0.5% for outpatients and 1.1% for hospitalized					
women. Four of the 11 had abnormal ALT, 7/11 had detectable HCV RNA. HCV genotypes were type one and three. HCV risks were present only in two women (occupation and promisquity). HCV					
one and three. HCV risks were present only in two women (occupation and promiscuity). HCV infection only correlated with age, older women had a higher prevalence (3.1%), younger women HCV					
rate was 0.6%. HCV infection did not correlate with ethnic background, job assignment, military rank					
or serum ALT level. In conclusion, HCV infection is silently present in military women.					
14. SUBJECT TERMS HCV Infecti			•		
Program, Hepatitis	on, pereme women a	mearch MesealC	11		
- · ·			16. PRICE CODE		

17. SECURITY CLASSIFICATION 18. SECURITY CLASSIFICATION 19. SECURITY CLASSIFICATION 20. LIMITATION OF ABSTRACT

OF ABSTRACT

Unclassified

OF THIS PAGE

Unclassified

OF REPORT

limited

FOREWORD

1	re not necessarily endorsed by the US Army.
	Where copyrighted material is quoted, permission has been obtained to use such material.
	Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.
	Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.
	In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).
	For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.
	In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.
	In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.
·	In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Maria H Sjogren, COL, MC 5 July 1996 Principal Investigator

INTRODUCTION

Chronic viral hepatitis is a major public health concern in the United States and the world. About 1% of blood donors and 1.4% of apparently healthy American individuals are infected with the hepatitis C virus (1). For the past five years we studied a military population referred to the Walter Reed Army Medical Center because of chronic hepatitis, the number of patients is slightly over 400. This patient population was characterized clinically and by serological markers as chronic hepatitis B and chronic hepatitis C. These subjects have participated in three major epidemiological studies (2,3,4) and in two therapeutic trials which are ongoing (5,6). Our patients are young with a mean age of 41 years (range 18-76 years old); the risk of infection with hepatitis viruses is largely unknown. Sexual transmission accounts for 8% of the infections (2,3). Most patients (95%) have detectable levels of viral replication markers (HBV DNA or HCV RNA, respectively). When liver biopsies are evaluated, 98% of patients have the diagnosis of chronic hepatitis. Many of these populations have reduced working hours because of associated symptomatology. About 2% have developed hepatocellular carcinoma. Approximately 50% of the patients with chronic viral hepatitis participated in therapeutic trials. Efficacy of the medications varied according to the therapeutic regimen and ranged between 10% and 40% for chronic hepatitis C and approximately 40% response for chronic hepatitis B (unpublished data). Preliminary study on the hepatitis C virus genotype shows a variety of genotypes (1a, 1b, 3a and possibly 7,8 and 9). This range of genotypes is likely due to the worldwide deployment of US military service members.

A gap in the knowledge regarding the prevalence of hepatitis C infection among military women was identified. As a result, the Department of Defense Women's Health Research Program funded a study where about 1,000 active duty women were tested for serological markers of hepatitis C. The analysis of this work is discussed in this manuscript.

BODY

Study Group

The study group included a total of 949 active duty females. Among them, 464 were healthy women and 485 women consulted a physician or were hospitalized for a variety of medical reasons which did not include liver disease. Demographic data and epidemiological risks of HCV infection were sought with the aid of a questionnaire.

		<u>"n"</u>
•	Group A: Healthy women	464
•	Group B: Clinic visits (not liver related)	396
•	Group C: Hospitalized (not liver related	_89
	Total	949

Serological assays

A serum specimen was collected from each subject. Sera were tested for makers of liver disease (alanine aminotransferase: ALT) and markers of HCV infection (antibody to HCV: anti-HCV).

- Anti-HCV was detected by ELISA 2.0 (Ortho Laboratories, Piscataway, NJ) and by RIBA-II (recombinant immunoblot assay) (Ortho Laboratories, Piscataway, NJ)
- In addition, sera with detectable anti-HCV, was further studied for the presence of viral RNA (HCV RNA) by qualitative and quantitative assays:
 - ► RT PCR (primers 5' UTR)
 - ▶ bDNA (Chiron Laboratories, Emeryville, CA)
 - ► Amplicor (Roche Laboratories, New Jersey)
- HCV genotype was assayed if HCV RNA was present in serum.
 - ► Inno-LIPA assay, Innogenetics Laboratories, Belgium

Questionnaire

The following information was obtained

• Demographics

Age (years)

Race

Military rank (officer or enlisted)
Job assignment (health care or office work)


Risk Factors
 Received blood products
 History of intravenous drug abuse
 History of liver disease
 Sexual activity with known HCV-infected partners
 Promiscuity (more than one sexual partner at a time)

Data Analysis

Data were analyzed for prevalence rates in each of the study groups. Overall prevalence of HCV in military active duty women was calculated.

Correlations between HCV infection and age, military rank, occupation, risk factors and serum ALT levels were done.

RESULTS



Of the 949 women, 11 (1.16%) tested positive for anti-HCV. Their demographic data and hepatitis C markers, HCV RNA and HCV genotype are depicted in Table 1. Of these 11, 4 had abnormal serum ALT levels ranging between 62 and 110 u/L.

Group A: HCV rate of 1.7% (8/464) and abnormal ALT rate of 1.7% (8/464).

Group B: HCV rate of 0.5% (2/396) and abnormal ALT rate of 2.8% (11/396).

Group C: HCV rate of 1.1% (1/89) and abnormal ALT rate of 7.9% (7/89).

TABLE 1
Serological Profile on the Eleven HCV-Infected Subjects

Patient	Age/Race	ALT * u/L	ELISA OD	RIBA II	HCV RNA (RT-PCR)	Genotype **
1	38/Black	24	2.5 (+)	Positive	Positive	1a
2	48/White	14	0.64 (+)	Negative	Negative	ND
3	35/White	26	2.5 (+)	Positive	Negative	ND
4	32/Black	39	1.27 (+)	Negative	Positive	1a,3
5	24/Hispanic	33	0.72 (+)	Negative	Positive	3
6	42/Unknown	18	1.04 (+)	Indeterm.	Negative	ND
7	28/White	110 ↑	2.5 (+)	Positive	Positive	1a
8	45/White	68 t	2.5 (+)	Positive	Positive	1b
9	27/White	62 ↑	2.5 (+)	Positive	Positive	1a
10	46/White	68↑	2.5 (+)	Positive	Positive	1a
11	43/Hispanic	37	2.5 (+)	Positive	Negative	ND

^{*} ALT normal level: 9-52

^{**} ND: HCV genotype cannot be done when HCV RNA is undetectable

TABLE 2

Comparison of Three Methods to Detect HCV RNA

Patient	HCV RNA (RT-PCR)	HCV RNA (CHIRON) bDNA Eq/mL x 10 ⁵	HCV RNA (ROCHE) Amplicor Copies/mL
1	Positive	27.11 (Positive)	340,135 (Positive)
2	Negative	< 3.5 (Negative)	(Negative)
3	Negative	< 3.5 (Negative)	(Negative)
4	Positive	< 3.5 (Negative)	(Negative)
5	Positive	< 3.5 (Negative)	(Negative)
6	Negative	< 3.5 (Negative)	(Negative)
7	Positive	15.9 (Positive)	134,161 (Positive)
8	Positive	196.2 (Positive)	458,900 (Positive)
9	Positive	8.6 (Positive)	81,760 (Positive)
10	Positive	14.1 (Positive)	105,600 (Positive)
11	Negative	< 3.5 (Negative)	(Negative)

Table 2 shows the comparison of three methods to detect HCV RNA. Our results are in agreement with the published literature, where the qualitative RT-PCR test is the most sensitive for detection of HCV RNA. The Chiron test and the Amplicor have the advantage of measuring titer of RNA in serum, however the sensitivity is low.

TABLE 3

Comparison of the Sensitivity of HCV RNA by RT-PCR, bDNA and Amplicor

	RIBA +	RIBA -	bDNA+	bDNA -	Amplicor +	Amplicor -
HCVRNA +	5	2	5	2	5	2
HCVRNA -	2	2	0	4	. 0	4
Amplicor +	5	0	5	0		
Amplicor -	2	4	0	6		
bDNA +	5	0				
bDNA -	2	4				

Of the 11 subjects that were Elisa positive, 7 were Riba positive, 7 were HCV RNA positive, 5 were bDNA positive and 5 were Amplicor positive.

Correlation of HCV infection and Demographics or Risk Factors

HCV infection correlated with age. Among young adults (age 18 - 30) the infection rate was 0.6% (3/487). While among adults aged 31 to 45 years, the infection rate was 1.5% (6 /396). In contrast, older adults (age > 45 years) the infection rate was 3.1% (2/64). HCV infection varied slightly among races. Caucasians had a 1.1% infection rate (6/543). African Americans had a 0.7% infection rate (2/287). Hispanics had a 3.9% infection rate (2/51). There were no Asian subjects with HCV (0/30).

Among the risk factors, HCV infection correlated with history of prior liver disease (other than viral hepatitis) and receipt of blood products. Anti-HCV was detectable in 10.5% of subjects who had prior liver disease (2/19) and in 2.9% (2/69) of subjects who had received blood products. HCV infection did not correlate with serum ALT (Figure 2), health status, military rank (Figure 3), or type of work. Overall the abnormal ALT rate was 2.7% (26/949)




Figure 2. Shows the lack of correlation between abnormal ALT and HCV infection.

Abnormal ALT

Group A: 1.7% (8/464)

Group B: 2.8% (11/396)

Group C: 7.9% (7/89).

Abnormal ALT did correlate with other risk factors (liver disease, blood products, and promiscuity) and health status. 7.1% of subjects who received blood products had abnormal serum ALT levels (5/70). 15.8% of subjects who have liver disease had abnormal ALTs (3/19). 4.2% of subjects who had more than one sexual partner the previous year had an abnormal serum ALT value. Abnormal ALT varied slightly among races as well. The rate of ALT abnormality was 2.9% among Caucasians (16/543), 2.4% among African Americans (7/289), 2% among Hispanics (1/51) and, 6.7% among Asians (2/30).




Figure 3. Depicts the same proportion of anti-HCV among officers (1.4%) and enlisted(1%)military women (p=.52)

The anti-HCV optical density of the Ortho assay was higher in patients with detectable HCV RNA (RT-PCR) than in patients with undetectable HCV RNA (Table 2). Quantitative HCV RNA tests were insensitive but provided titer of the viral RNA when positive.

CONCLUSIONS

Hepatitis C infection is detectable in military women at similar rates as reported in the civilian population. However, this infection appears to be silent. The HCV genotypes observed were type 1 and 3, which are known to associate with progressive liver disease. These women are at risk of significant liver disease. Clinical monitoring of these subjects is in order. Since the start of this study, a new hepatitis virus has been discovered, the hepatitis G (HGV) (6). It is known to associate to HCV infection. It would be of importance to test this serum collection for HGV. Similarly, a study of service men in the same categories as the studied women needs to be carried out.

BIBLIOGRAPHY

- 1. Gastroenterology Clinics of North America 1994;23:437-455
- 2. Proceedings of International Symposium on Viral hepatitis and Liver Disease, Tokyo, Japan, 1994: 450-454
- 3. Gastroenterology 1994;106:A998
- 4. Gastroenterology 1996;110:A1330
- 5. Hepatology 1994;20:2007A
- 6. Science 1996;271:505-508
- 6. Walter Reed Army Medical Center, Clinical Trial WU# 9296

DEPARTMENT OF THE ARMY



US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND 504 SCOTT STREET FORT DETRICK, MARYLAND 21702-5012

REPLY TO ATTENTION OF:

MCMR-RMI-S (70-1y)

10 Aug 98

MEMORANDUM FOR Administrator, Defense Technical Information Center, ATTN: DTIC-OCP, Fort Belvoir, VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for the following contracts. Request the limited distribution statement for these contracts be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

<u>Contract Number</u>	Accession Document Number
DAMD17-91-C-1020	ADB187724 🛧 🗸
DAMD17-92-C-2053	ADB196427 +
DAMD17-94-C-4022	ADB190750 +
DAMD17-94-C-4023	ADB188373 +
DAMD17-94-C-4027	ADB196161 🗚
DAMD17-94-C-4029	ADB190899 1-
DAMD17-94-C-4039	ADB188023 †
DAMD17-94-C-4024	ADB189184 +
DAMD17-94-C-4026	ADB187918 ∤
DAMD17-94-J-4250	ADB221970
DAMD17-94-J-4250	ADB230700
DAMD17-96-1-6241	x ADB233224
DAMD17-96-1-6241	ADB218632 ✓
DAMD17-94-J-4496	∠ ADB225269
DAMD17-94-J-4392	ADB225308 ✔
DAMD17-94-J-4455	ADB225784 ✓
DAMD17-94-J-4309	ADB228198 ✓
DAMD17-91-C-1135	ADB233658 ✓
DAMD17-94-J-4038	ADB232313 🗸
DAMD17-94-J-4073	ADB222794 ✓
DAMD17-94-J-4131	ADB219168 ✔
DAMD17-94-J-4159	ADB232305 ✓
мгрх· 95MM5535	ADB232218
95MM5605	ADB233374
95MM5673	ADB226037

MCMR-RMI-S

SUBJECT: Request Change in Distribution Statement

2. Point of contact for this request is Ms. Judy Pawlus at DSN 343-7322 or email: judy_pawlus@ftdetrck-ccmail.army.mil.

FOR THE COMMANDER:

HYLIS M. RINEHART

Deputy Chief of Staff for Information Management